Global pharmaceutical companies are ramping up pressure on European governments over healthcare spending controls. Germany has become the latest focal point of intense industry resistance. Drugmakers facing tighter financial regulations across Europe are deploying a familiar strategy. They are warning policymakers that local investments, facility expansions, and patient access to life-saving medicines are at risk. This playbook recently delivered major…